Kociolek Lab - Infection prevention & control

The Kociolek laboratory houses a translational research program focused on various aspects of pediatric healthcare epidemiology and infection prevention and control, particularly Clostridium difficile colonization and infection in children. This research program is integrated with the Host-Microbial Interactions, Inflammation, and Immunity (HMI3) Program at the Stanley Manne Children’s Research Institute at Lurie Children’s. Our laboratory is primarily focused on various aspects of C. difficile colonization and infection, including clinical and molecular epidemiology, genomics, clinical microbiology and diagnosis, antibiotic resistance, and host immune response. Our overarching goal is to rigorously investigate this important pathogen in children to improve our ability to diagnose, prevent, and treat this infection.

Current Research Projects

  • Optimizing the diagnosis of pediatric C. difficile infection
    • The primary goal of this NIAID K23-supported study is to comprehensively assess the effectiveness of commercially available diagnostic tests and diagnostic tests in development for differentiating C. difficile colonization and infection in children. Using whole genome sequencing, we are seeking to identify genomic biomarkers that may differentiate strains that colonize vs. those that infect.
  • Immunologic consequences of infant C. difficile colonization
    • This prospective cohort study seeks to identify the incidence and molecular epidemiology of C. difficile colonization in infants, as well as the association between toxigenic C. difficile colonization and development of potentially protective anti-toxin antibody responses in infants.

Laboratory Members

Abdullahi Abdi - Master's Student
Jayabrata Mukherjee - Research Associate III
Kathryn Cherny, Postdoctoral Associate

Contact Information

Larry K. Kociolek, MD, MSCI, Assistant Professor of Pediatrics, Northwestern University Feinberg School of Medicine; Attending Physician, Division of Infectious Diseases, Associate Medical Director of Infection Prevention and Control, Ann & Robert H. Lurie Children’s Hospital of Chicago
Searle Medical Research Building
320 E Superior St, Room 15-560
Chicago, IL 60611
Lab Phone 312.503.6918 | Hospital Office Phone 312.227.4080 | Fax 312.227.9709
Email: larry-kociolek@northwestern.edu


A. Peer-reviewed Original Investigations

Kociolek LK, Gerding DN, Espinosa RO, Patel SJ, Shulman ST, Ozer EA. Clostridium difficile Whole Genome Sequencing Reveals Limited Transmission Among Symptomatic Children: A Single-Center Analysis. Clinical Infectious Diseases 2018; In press.

Kociolek LK, Gerding DN, Hecht DW, Ozer EA. Comparative genomics analysis of Clostridium difficile epidemic strain DH/NAP11/106. Microbes and Infection 2018; In press.

Patel RM, Kociolek LK, Merrick E, Reuter C, Kronforst K, Zheng X, Patel SJ. Safety of Palivizumab Stewardship in Conjunction with Infection Prevention Strategies for Healthcare-Associated Respiratory Suncytial Virus Infections. Infection Control and Hospital Epidemiology 2018; In press.

Kociolek LK, Ozer EA, Gerding DN, Hecht DW, Patel SJ, Hauser AR. Whole Genome Analysis Reveals the Evolution and Transmission of a Multidrug-Resistant DH/NAP11/106 Clostridium difficile Clone in a Pediatric Hospital. Journal of Antimicrobial Chemotherapy 2018; In press.

Chao Y, Reuter C, Kociolek LK, Patel R, Zheng X, Patel S. Optimizing empiric therapy for gram-negative bloodstream infections in children. Journal of Hospital Infection 2017; Epub ahead of print. doi: 10.1016/j.jhin.2017.09.018.

Corkum KS, Jones RE, Reuter CH, Kociolek LK, Morgan E, Lautz TB. Central venous catheter salvage in children with Staphylococcus aureus central line-associated bloodstream infection. Pediatric Surgery International 2017; Epub ahead of print. doi: 10.1007/s00383-017-4165-5.

Ozer EA, Hauser AH, Gerding DN, Espinosa RO, Hecht DW, Kociolek LK. Complete Genome Sequence of Clostridioides difficile Epidemic Strain DH/NAP11/106/ST-42 Isolated from Stool from a Pediatric Patient with Diarrhea. Genome Announcements 2017; 5:e00923-17. https://doi.org/10.1128/genomeA.00923-17.

O’Gorman MA, Michaels MG, Kaplan SL, Otley A, Kociolek LK, Hoffenberg EJ, Kim SW, Nachman S, Pfefferkorn MD, Sentongo T, Sullivan JE, Sears P. A Safety and Pharmacokinetic Study of Fidaxomicin in Children with Clostridium difficile-associated Diarrhea: A Phase 2a Multicenter Clinical Trial. Journal of the Pediatric Infectious Diseases Society 2017; Epub ahead of print, doi: 10.1093/jpids/pix037.

Spiekerman KM, Patel SJ, Patel R, Kociolek LK. Availability, perceptions, and characteristics of antibiograms among Illinois pediatricians. Infection and Drug Resistance 2016;9:269-274.

Kociolek LK, Gerding DN, Osmolski JR, Patel SJ, Snydman DR, McDermott LA, Hecht DW. Differences in the molecular epidemiology and antibiotic susceptibility of Clostridium difficile in pediatric and adult patients. Antimicrobial Agents and Chemotherapy 2016;60(8):4896-4900. doi:10.1128/AAC.00714-16.

Kociolek LK, Bovee M, Carter D, Ciolino JD, Patel R, O’Donnell A, Rupp AH, Zheng X, Shulman ST, Patel SJ. Impact of a Healthcare Provider Educational Intervention on Frequency of Clostridium
difficile PCR Testing in Children: A Segmented Regression Analysis. Journal of the Pediatric Infectious Diseases Society 2016;6(2):142-8. doi: 10.1093/jpids/piw027.

Kociolek LK, Patel SJ, Zheng X, Todd KM, Shulman ST, Gerding DN. Clinical and microbiologic assessment of cases of pediatric community-associated Clostridium difficile infection reveals opportunities for improved testing decisions. Pediatric Infectious Diseases Journal 2016;35(2):157-161. doi: 10.1097/INF.0000000000000954

Kociolek LK, Patel SJ, Shulman ST, Gerding DN. Concomitant medical conditions and therapies preclude accurate classification of children with severe or severe complicated Clostridium difficile infection. Journal of the Pediatric Infectious Diseases Society 2015;4(4):e139-e142. doi: 10.1093/jpids/piu121.

Kociolek LK, Palac HL, Patel SJ, Shulman ST, Gerding DN. Risk factors for recurrent Clostridium difficile infection in children: A nested case-control study. Journal of Pediatrics 2015;167(2):384-9. doi: 10.1016/j.jpeds.2015.04.052.

Kociolek LK, Patel SJ, Shulman ST, Gerding DN. Molecular epidemiology of Clostridium difficile infections in children: A retrospective cohort study. Infection Control and Hospital Epidemiology 2015;36(4):445-51. doi: 10.1017/ice.2014.89.

Kociolek LK, Sandora TJ. National variability in surveillance, testing, and infection prevention for Clostridium difficile infection in pediatric populations. American Journal of Infection Control 2013;41(10):933-5. doi: 10.1016/j.ajic.2013.02.020.

B. Invited Reviews and Commentaries

Kociolek LK. Clostridium difficile and commonly used medications. Journal of Pediatrics 2017;190:287-290. doi: 10.1016/j.jpeds.2017.08.052.

Kociolek LK, Shulman ST. Biotherapeutics for the Prevention of Clostridium difficile Infection. Infectious Disease Advisor. Haymarket Media, Inc. 16 Aug 2017. Web. http://www.infectiousdiseaseadvisor.com/clostridium-difficile/biotherapeutics-clostridium-difficile-infection-prevention/article/682005/

Kociolek LK, Shulman ST. Clostridium difficile Treatment and Prevention: Novel Antibiotics and Immunologic Therapies. Infectious Disease Advisor. Haymarket Media, Inc., 8 June. 2017. Web. http://www.infectiousdiseaseadvisor.com/clostridium-difficile/c-difficile-novel-antibiotics-immunologic-therapies/article/666866/

Kociolek LK, Shulman ST. Review of Clostridium difficile vaccines in development. Infectious Disease Advisor. Haymarket Media, Inc., 24 Mar. 2017. Web. http://www.infectiousdiseaseadvisor.com/clostridium-difficile/status-of-clostridium-difficile-vaccines/article/646015/

Kociolek LK. Strategies for Optimizing the Diagnostic Predictive Value of Clostridium difficile Molecular Diagnostics. Journal of Clinical Microbiology 2017;55(5):1244-8. doi:10.1128/JCM.00147-17.

Kociolek LK, Gerding DN. Breakthroughs in the treatment and prevention of Clostridium difficile infections. Nature Reviews Gastroenterology and Hepatology 2016;13(3):150-60. doi: 10.1038/nrgastro.2015.220.

Burnham CA, Dubberke ER, Kociolek LK, Polage CR, Riley TV. Clostridium difficile- Diagnostic and Clinical Challenges. Clinical Chemistry 2016;62(2):310-4. doi: 10.1373/clinchem.2015.243717.

Kociolek LK, Gerding DN. Clinical utility of laboratory detection of Clostridium difficile strain BI/NAP1/027. Journal of Clinical Microbiology 2016;54(1):19-24. doi: 10.1128/JCM.02340-15

Lateef O, Hota B, Landon E, Kociolek LK, Morita J, Black S, Noskin G, Kelleher M, Curell K, Galat A, Ansell D, Segreti J, Weber SG. CERN: A city-wide cross-hospital collaborative for infectious diseases preparedness. Clinical Infectious Diseases 2015;61(10):1554-7. doi: 10.1093/cid/civ510

Kociolek LK, Gerding DN. Is pediatric Clostridium difficile infection associated with prior antibiotic use? Future Microbiology 2014;9(7):825-8. doi: 10.2217/fmb.14.51.

Kociolek LK, Shulman ST. In the clinic: Pharyngitis. Annals of Internal Medicine. 2012;157(5):ITC3-1 – ITC3-16. doi: 10.7326/0003-4819-157-5-20120904-01003.

C. Books and Book Chapters

Kociolek LK, Bovee M. Infection Prevention and Control in the Hospital. In: Pediatric Infectious Diseases: Essentials for Practice, 2nd Ed. New York, NY: McGraw-Hill Education; In press.